386 related articles for article (PubMed ID: 21482486)
21. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
23. Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection.
Klastersky J; Paesmans M
Support Care Cancer; 2007 Feb; 15(2):137-41. PubMed ID: 16967301
[TBL] [Abstract][Full Text] [Related]
24. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Johnson JR
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12037157
[No Abstract] [Full Text] [Related]
25. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.
Powers JH; Dixon CA; Goldberger MJ
N Engl J Med; 2002 Jan; 346(4):289-90. PubMed ID: 11807157
[No Abstract] [Full Text] [Related]
26. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Apisarnthanarak A; Little JR; Tebas P
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527
[No Abstract] [Full Text] [Related]
27. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Ullmann AJ; Heussel CP; Cornely OA
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
[No Abstract] [Full Text] [Related]
28. Voriconazole versus amphotericin B for invasive aspergillosis.
Karthaus M
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12494937
[No Abstract] [Full Text] [Related]
29. Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies.
Herbrecht R
Ann Hematol; 2002; 81 Suppl 2():S52-3. PubMed ID: 12611078
[No Abstract] [Full Text] [Related]
30. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
31. Combination antifungal therapy for invasive aspergillosis.
Cesaro S; Visintin G
Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
[No Abstract] [Full Text] [Related]
32. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
33. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis.
Chamilos G; Kontoyiannis DP
J Infect; 2005 Nov; 51(4):e225-8. PubMed ID: 16291275
[TBL] [Abstract][Full Text] [Related]
34. Invasive aspergillosis: current and future challenges in diagnosis and therapy.
Hope WW; Denning DW
Clin Microbiol Infect; 2004 Jan; 10(1):2-4. PubMed ID: 14706080
[TBL] [Abstract][Full Text] [Related]
35. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole.
Forestier E; Remy V; Lesens O; Martinot M; Hansman Y; Eisenmann B; Christmann D
Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):347-9. PubMed ID: 15889298
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease.
van 't Hek LG; Verweij PE; Weemaes CM; van Dalen R; Yntema JB; Meis JF
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1694-6. PubMed ID: 9603157
[TBL] [Abstract][Full Text] [Related]
37. Invasive pulmonary and cerebral aspergillosis in a patient with Weil's disease.
Cocchi S; Codeluppi M; Guaraldi G; Squillace N; Bedini A; Venturelli C; Esposito R
Scand J Infect Dis; 2005; 37(5):396-8. PubMed ID: 16051585
[TBL] [Abstract][Full Text] [Related]
38. Decisions about voriconazole versus liposomal amphotericin B.
Walsh TJ; Lee J; Dismukes WE
N Engl J Med; 2002 May; 346(19):1499; author reply 1499. PubMed ID: 12000825
[No Abstract] [Full Text] [Related]
39. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
40. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.
Frankenbusch K; Eifinger F; Kribs A; Rengelshauseu J; Roth B
J Perinatol; 2006 Aug; 26(8):511-4. PubMed ID: 16871222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
